1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine has been researched along with Abnormal Movements in 18 studies
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A dopaminergic neurotoxic compound which produces irreversible clinical, chemical, and pathological alterations that mimic those found in Parkinson disease.
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine : A tetrahydropyridine that is 1,2,3,6-tetrahydropyridine substituted by a methyl group at position 1 and a phenyl group at position 4.
| Excerpt | Relevance | Reference |
|---|---|---|
| " During long-term levodopa therapy, patients develop abnormal movements, dyskinesias, the pathophysiological basis of which is poorly understood." | 3.70 | Internal globus pallidus discharge is nearly suppressed during levodopa-induced dyskinesias. ( Desimone, R; Fiorani, M; Oldfield, EH; Papa, SM, 1999) |
| "To investigate the role of the basal ganglia in parkinsonian tremor, we recorded hand tremor and simultaneous activity of several neurons in the external and internal segments of the globus pallidus (GPe and GPi) in two vervet monkeys, before and after systemic treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and development of parkinsonism with tremor of 5 and 11 Hz." | 3.70 | Firing patterns and correlations of spontaneous discharge of pallidal neurons in the normal and the tremulous 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine vervet model of parkinsonism. ( Bergman, H; Raz, A; Vaadia, E, 2000) |
| "Levodopa treatment could induce protective cardiac effects through the increased Hsp27 activity." | 1.56 | Cardiac Noradrenaline Turnover and Heat Shock Protein 27 Phosphorylation in Dyskinetic Monkeys. ( Almela, P; Bautista-Hernández, V; Cuenca-Bermejo, L; de Pablos, V; Estrada, C; Fernández-Villalba, E; Herrero, MT; Laorden, ML; Yuste, JE, 2020) |
| "The development of dyskinesias following chronic L-DOPA replacement therapy remains a major problem in the long-term treatment of Parkinson's disease." | 1.39 | IRC-082451, a novel multitargeting molecule, reduces L-DOPA-induced dyskinesias in MPTP Parkinsonian primates. ( Aron Badin, R; Auguet, M; Bertrand, A; Boulet, S; Brouillet, E; Chabrier, PE; Dollé, F; Gaillard, MC; Guillermier, M; Hantraye, P; Jan, C; Malgorn, C; Savasta, M; Spinnewyn, B; Van Camp, N, 2013) |
| "In reserpine-treated animals, specific delta opioid binding was increased in premotor cortex (+30%), sensorimotor striatum (+20%), and associative striatum (+17%) rostrally, but was not changed in caudal forebrain." | 1.34 | Striatal delta opioid receptor binding in experimental models of Parkinson's disease and dyskinesia. ( Brotchie, JM; Hallett, PJ, 2007) |
| "The improvement of parkinsonism in all animals treated with l-Dopa alone was clearly displayed from the first day of treatment." | 1.33 | Naltrexone in the short-term decreases antiparkinsonian response to l-Dopa and in the long-term increases dyskinesias in drug-naïve parkinsonian monkeys. ( Bédard, PJ; Di Paolo, T; Grégoire, L; Hadj Tahar, A; Rouillard, C; Samadi, P, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (11.11) | 18.2507 |
| 2000's | 8 (44.44) | 29.6817 |
| 2010's | 7 (38.89) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Almela, P | 1 |
| Cuenca-Bermejo, L | 1 |
| Yuste, JE | 1 |
| Estrada, C | 1 |
| de Pablos, V | 1 |
| Bautista-Hernández, V | 1 |
| Fernández-Villalba, E | 1 |
| Laorden, ML | 1 |
| Herrero, MT | 1 |
| Lin, JG | 1 |
| Chen, CJ | 1 |
| Yang, HB | 1 |
| Chen, YH | 1 |
| Hung, SY | 1 |
| Porras, G | 2 |
| De Deurwaerdere, P | 1 |
| Li, Q | 2 |
| Marti, M | 1 |
| Morgenstern, R | 1 |
| Sohr, R | 1 |
| Bezard, E | 3 |
| Morari, M | 1 |
| Meissner, WG | 1 |
| Urs, NM | 1 |
| Bido, S | 1 |
| Peterson, SM | 1 |
| Daigle, TL | 1 |
| Bass, CE | 1 |
| Gainetdinov, RR | 1 |
| Caron, MG | 1 |
| Ahmed, MR | 1 |
| Berthet, A | 1 |
| Bychkov, E | 1 |
| Bioulac, BH | 1 |
| Carl, YT | 1 |
| Bloch, B | 1 |
| Kook, S | 1 |
| Aubert, I | 1 |
| Dovero, S | 1 |
| Doudnikoff, E | 1 |
| Gurevich, VV | 1 |
| Gurevich, EV | 1 |
| Huot, P | 1 |
| Johnston, TH | 1 |
| Koprich, JB | 1 |
| Aman, A | 1 |
| Fox, SH | 3 |
| Brotchie, JM | 4 |
| Anandhan, A | 1 |
| Essa, MM | 1 |
| Manivasagam, T | 1 |
| Aron Badin, R | 1 |
| Spinnewyn, B | 1 |
| Gaillard, MC | 1 |
| Jan, C | 1 |
| Malgorn, C | 1 |
| Van Camp, N | 1 |
| Dollé, F | 1 |
| Guillermier, M | 1 |
| Boulet, S | 1 |
| Bertrand, A | 1 |
| Savasta, M | 1 |
| Auguet, M | 1 |
| Brouillet, E | 1 |
| Chabrier, PE | 1 |
| Hantraye, P | 1 |
| Quik, M | 1 |
| Police, S | 1 |
| Langston, JW | 1 |
| Di Monte, DA | 1 |
| Smith, LA | 1 |
| Tel, BC | 1 |
| Jackson, MJ | 1 |
| Hansard, MJ | 1 |
| Braceras, R | 1 |
| Bonhomme, C | 1 |
| Chezaubernard, C | 1 |
| Del Signore, S | 1 |
| Rose, S | 1 |
| Jenner, P | 1 |
| Bibbiani, F | 1 |
| Costantini, LC | 1 |
| Patel, R | 1 |
| Chase, TN | 1 |
| Samadi, P | 1 |
| Grégoire, L | 1 |
| Hadj Tahar, A | 1 |
| Di Paolo, T | 1 |
| Rouillard, C | 1 |
| Bédard, PJ | 1 |
| Hallett, PJ | 1 |
| Henry, B | 2 |
| Peggs, D | 1 |
| Crossman, AR | 2 |
| Papa, SM | 1 |
| Desimone, R | 1 |
| Fiorani, M | 1 |
| Oldfield, EH | 1 |
| Raz, A | 1 |
| Vaadia, E | 1 |
| Bergman, H | 1 |
| Chassain, C | 1 |
| Eschalier, A | 1 |
| Durif, F | 1 |
18 other studies available for 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and Abnormal Movements
| Article | Year |
|---|---|
Cardiac Noradrenaline Turnover and Heat Shock Protein 27 Phosphorylation in Dyskinetic Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dyskinesias; HSP27 Heat-Shock Proteins; Levod | 2020 |
Electroacupuncture Promotes Recovery of Motor Function and Reduces Dopaminergic Neuron Degeneration in Rodent Models of Parkinson's Disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apoptosis; Brain-Derived Neurotrophic Factor; | 2017 |
L-dopa-induced dyskinesia: beyond an excessive dopamine tone in the striatum.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benserazide; Corpus Striatum; Disease Models, | 2014 |
Targeting β-arrestin2 in the treatment of L-DOPA-induced dyskinesia in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Arrestins; Behavior, Animal; beta-Arrestins; | 2015 |
Lentiviral overexpression of GRK6 alleviates L-dopa-induced dyskinesia in experimental Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Behavior, Animal; Dose- | 2010 |
L-745,870 reduces L-DOPA-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Brain; Drug Interaction | 2012 |
Therapeutic attenuation of neuroinflammation and apoptosis by black tea theaflavin in chronic MPTP/probenecid model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antioxidants; Apoptosis; bcl-2-Associated X P | 2013 |
IRC-082451, a novel multitargeting molecule, reduces L-DOPA-induced dyskinesias in MPTP Parkinsonian primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antioxidants; Antiparkinson Agent | 2013 |
Increases in striatal preproenkephalin gene expression are associated with nigrostriatal damage but not L-DOPA-induced dyskinesias in the squirrel monkey.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Corpus Striatum; Dopamine Ag | 2002 |
Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Arousal; Callithrix; Ca | 2002 |
Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Apomorphine; Disease Mo | 2005 |
Naltrexone in the short-term decreases antiparkinsonian response to l-Dopa and in the long-term increases dyskinesias in drug-naïve parkinsonian monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Antiparkinson Agents; B | 2005 |
Striatal delta opioid receptor binding in experimental models of Parkinson's disease and dyskinesia.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Corpus Striatum; Diseas | 2007 |
The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic Antagonists; Animals; Antiparkinson Agents; | 1999 |
Internal globus pallidus discharge is nearly suppressed during levodopa-induced dyskinesias.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Carbidopa; Drug Combina | 1999 |
Firing patterns and correlations of spontaneous discharge of pallidal neurons in the normal and the tremulous 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine vervet model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Animals; Biological Clocks; Chloroc | 2000 |
Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Callithrix; Disease Models, Animal; Drug Ther | 2001 |
Assessment of motor behavior using a video system and a clinical rating scale in parkinsonian monkeys lesioned by MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Basal Ganglia; Behavior | 2001 |